MedTrace Logo

Abemaciclib for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia.

NCT05789771 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 136

Last updated 2023-03-31

No results posted yet for this study

Summary

The ATLANT study is prospective, multicentre, non-interventional, observational study. Patients with HR+/HER2-negative metastatic breast cancer received abemaciclib as monotherapy or in combination with endocrine therapy.

Conditions

Interventions

DRUG

Abemaciclib

Abemaciclib 150 mg orally every 12 hours plus Aromatase Inhibitor ( Anastrozole 1 mg, Letrozole 2.5 mg or exemestane 25 mg orally every 24 hours on Days 1 to 28 of a 28-day cycle)

DRUG

Abemaciclib

Abemaciclib 150 mg orally every 12 hours plus Fulvestrant (500 mg intramuscularly on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond on Day 1 of a 28-day cycle)

DRUG

Abemaciclib

Abemaciclib 200 mg orally every 12 hours

Sponsors & Collaborators

  • Russian Society of Clinical Oncology

    collaborator UNKNOWN

  • Blokhin's Russian Cancer Research Center

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2022-12-01
Completion
2022-12-01
FDA Drug
Yes

Countries

  • Russia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05789771 on ClinicalTrials.gov